This article is more than 5 years old. Information may no longer be current.
ISCHEMIA highlights newly announced AHA late-breaking clinical trials
Click Here to Manage Email Alerts
New data from CV prevention and treatment trials are among the late-breaking clinical trials selected for presentation at the American Heart Association Scientific Sessions from Nov. 16 to 18 in Philadelphia.
The late-breaking clinical trials include ISCHEMIA, which was an international study that assessed management strategies for patients with stable ischemic heart disease. Researchers will present data on clinical outcomes, quality-of-life outcomes and results in patients with chronic kidney disease in three separate presentations.
More results from the DAPA-HF trial of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) will also be presented, including outcomes in patients without diabetes, the effect of treatment based on age and the effect of treatment assessed by the Kansas City Cardiomyopathy Questionnaire. As Healio previously reported, dapagliflozin reduced risk for worsening HF and CV death when added to standard therapy in patients with HF, with or without diabetes.
Two presentations will focus on more data from the PARAGON-HF trial, including the effects of sacubitril/valsartan (Entresol, Novartis) in women compared with men and a secondary analysis across the spectrum of ejection fraction. As Healio previously reported, sacubitril/valsartan did not reduce the rate of hospitalizations for CV-related death and HF among patients with HF with preserved ejection fraction.
Results from ORION-9 and ORION-10 will be presented, which assessed inclisiran (The Medicines Company) among patients with heterozygous familial hypercholesterolemia and those with atherosclerotic CVD and elevated LDL, respectively.
The effects of icosapent ethyl (Vascepa, Amarin) were evaluated in patients on statin therapy with elevated triglycerides in the EVAPORATE trial.
The lineup also features a number of trials on management strategies for patients who underwent interventional procedures including the GALILEO study of rivaroxaban (Xarelto, Janssen/Bayer) vs. an antiplatelet-based strategy among patients who had transcatheter aortic valve replacement and COLCHICINE-PCI, a study of the effectiveness of administering colchicine periprocedurally during PCI.
Cardiology Today and Healio will be reporting live from the meeting. Stay tuned for news, videos, perspectives and more.